Teva Pharmaceutical Industries Ltd (TEVJF) Net Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVJF) quarterly Net Margin came in at 13.91% in Q2 2026, down 2064.0% YoY from 0.71% in Q2 2025, and down 249.66% on a QoQ basis from 9.29% in Q1 2026.
Teva Pharmaceutical Industries Ltd (TEVJF) Net Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVJF) has 18 years of Net Margin data on file, last reported at 13.91% in Q2 2026.
- Quarterly Net Margin fell 2064.0% year-over-year to 13.91% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 4.02% (up 511.0% YoY) and the FY2025 annual result came in at 8.13%, up 1998.0% from the prior year.
- Net Margin slipped to 13.91% in Q2 2026, from 9.29% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 13.59% in Q1 2024 to a low of 40.3% in Q4 2023.
- A 5-year average of 7.43% and a median of 7.13% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin tumbled 3066 bps — and 2024, when it surged 3081 bps.
- Tracing TEVJF's Net Margin over 5 years: stood at 34.35% in 2022, then fell by 17 bps to 40.3% in 2023, then surged by 76 bps to 9.48% in 2024, then soared by 205 bps to 9.98% in 2025, then plunged by 239 bps to 13.91% in 2026.
- The last three Net Margin figures came in at 13.91% (Q2 2026), 9.29% (Q1 2026), and 9.98% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.91% |
| Mar 31, 2026 | 9.29% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 9.64% |
| Jun 30, 2025 | 6.73% |
| Mar 31, 2025 | 5.65% |
| Dec 31, 2024 | -9.48% |
| Sep 30, 2024 | -9.07% |
| Jun 30, 2024 | -21.04% |
| Mar 31, 2024 | 13.59% |
| Dec 31, 2023 | -40.30% |
| Sep 30, 2023 | 1.97% |
| Jun 30, 2023 | -23.39% |
| Mar 31, 2023 | -6.91% |
| Dec 31, 2022 | -34.35% |
| Sep 30, 2022 | 1.78% |
| Jun 30, 2022 | -7.34% |
| Mar 31, 2022 | -26.58% |
| Dec 31, 2021 | -3.68% |
| Sep 30, 2021 | 7.87% |